KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNTech SE (BNTX) Work In Process: 2018-2021

  • BioNTech SE's Work In Process rose 317.92% to $96.7 million in Q4 2021 from the same period last year, while for Dec 2021 it was $96.7 million, marking a year-over-year increase of 317.92%. This contributed to the annual value of $96.7 million for FY2021, which is 317.92% up from last year.
  • Latest data reveals that BioNTech SE reported Work In Process of $96.7 million as of Q4 2021, which was up 317.92% from $23.1 million recorded in Q4 2020.
  • In the past 5 years, BioNTech SE's Work In Process registered a high of $96.7 million during Q4 2021, and its lowest value of $91,312 during Q4 2018.
  • Its 3-year average for Work In Process is $41.0 million, with a median of $23.1 million in 2020.
  • Data for BioNTech SE's Work In Process shows a peak YoY spiked of 3,400.86% (in 2019) over the last 5 years.
  • BioNTech SE's Work In Process (Quarterly) stood at $91,312 in 2018, then skyrocketed by 3,400.86% to $3.2 million in 2019, then surged by 623.57% to $23.1 million in 2020, then spiked by 317.92% to $96.7 million in 2021.
  • Its Work In Process was $96.7 million in Q4 2021, compared to $23.1 million in Q4 2020 and $3.2 million in Q4 2019.